Slide 1: Q4 and FY 2025 Financial Results
Q4 and FY 2025 Financial Results February 17, 2026 Nasdaq: NEO
Slide 2: Safe Harbor Statements
Safe Harbor Statements This presentation has been prepared by NeoGenomics, Inc. (“we,” ”us,” “our,” “NeoGenomics” or the “Company”). Statements contained herein are made as of the date of this presentation unless stated otherwise. This presentation includes forward-looking statements. These forward-
Slide 3: Mission and Vision
Mission We save lives by improving patient care. Vision We are becoming the world’s leading provider of comprehensive cancer testing, data and solutions through uncompromising quality, exceptional customer experience, and innovative products and services.
Slide 4: A foundation enabling momentum
A foundation enabling momentum 04 A “pure play” oncology solutions provider Entering the rapidly-growing $20+ billion solid 01 driving rapid dissemination and adoption of 04 tumor MRD (minimum residual disease) cancer monitoring market with the launch of RaDaR ST innovation through its best-in-class
Slide 5: One provider from diagnosis to recurrence monitoring
One provider from diagnosis to recurrence monitoring MRD Diagnostic Testing Therapy Selection Recurrence Monitoring $12B $13B $20B Penetration: 70% 35% <8% Flagship products: Sources: SEER, NCCN, NHS, NSF, NIH, UN, WHO, Precedence Research, primary market research, Precision for Medicine analysis, N
Slide 6: Strong revenue growth in 2025
Strong revenue growth in 2025 Q4 Revenue ($M) FY’25 Revenue ($M) $190M $727M $172M $661M 11% 10% YoY YoY growth growth Q4 2024 Q4 2025 FY 2024 FY 2025 Quarterly financial information is unaudited. Growth corresponds to prior year period. Reference non-GAAP reconciliation slides in quarterly filings
Slide 7: Launching RaDaR ST for MRD in Feb'26
Launching RaDaR® ST for MRD in Feb’26 Tapping into the large, nascent, & rapidly growing cancer recurrence monitoring market RaDaR ST Next-Gen MRD New MolDx reimbursement Indication Diagnosis Prevalence secured • Based on Whole Genome Sequencing (WGS) Head and neck 20K 60K Specialized • Capable of U
Slide 8: Expanding the PanTracer portfolio with Pro
Expanding the PanTracer portfolio with Pro Eliminating order complexity, PanTracer Pro delivers the right tests at the right time, and accelerates therapy decision-making with timely, relevant results to improve patient outcomes. Actionable information Reduces delays in Optimized workflow Includes o
Slide 9: Sales force expansion driving accelerated penetration
Sales force expansion driving accelerated penetration ~75% of community oncologists new to NEO in 2025 order 5+ tests NEO Community Oncologist NPI and Sales Headcount Trends, 2023-2025 Demonstrated ability of taking market share even 9,000*+ with later product introductions due to our strengths 8,00
Slide 10: Business levers for accelerated financial performance
Business levers for accelerated financial performance Product Commercial Execution Operations • RaDaR ST adoption in • Sales force expansion • Digital pathology Head and Neck, Breast • Pricing and Revenue Cycle • Use of automation & AI • RaDaR ST indication Management initiatives • Instrument platfo
Slide 11: 4Q'25 Highlights
4Q’25 Highlights Key Takeaways Clinical Clinical Revenue Volume Rev/Test Revenue Reported 16% 11% 5% Volume Same store 14% 6% 7% $190M | 11% growth 356K | 11% growth • NGS revenue grew 23% over prior year • Adjusted EBITDA of $13M is the 10th consecutive quarter of positive earnings Adj. Adj. • Adju
Slide 12: FY 2025 Highlights
FY 2025 Highlights Key Takeaways Clinical Clinical Revenue Volume Rev/Test Revenue Reported 15% 12% 3% Volume Same store 13% 9% 4% $727M | 10% growth 1.4M | 12% growth • NGS revenue grew 22% over prior year • Adjusted EBITDA of $43M or 9% growth from prior year Adj. Adj. • Adjusted Gross Profit of $
Slide 13: Initiating Full Year 2026 Guidance
Initiating Full Year 2026 Guidance Guidance as of February 17th, 2026 Guide ($ Millions) YoY% Growth Assumptions • Continued momentum in NGS Revenue $793 - $801 ~10% • • RaDaR revenue in MSD millions Modest revenue contribution from at midpoint PanTracer LBx • Non-clinical down LSD-MSD YoY Adj. EBID
Slide 14: Upcoming key catalysts
Upcoming key catalysts 1 RaDaR ST launch for HPV- Head & Neck, subset of Breast 2 PanTracer LBx MolDx reimbursement 3 Expanded indication reimbursement for RaDaR ST 4 Above market NGS growth
Slide 15: © 2026 NeoGenomics Laboratories, Inc. All rights reserved. All other trademarks are the property
© 2026 NeoGenomics Laboratories, Inc. All rights reserved. All other trademarks are the property of their respective owners. Rev. 02.17.2026